Browse
Submit Data
Databases
API
Help

Dataset Information

22 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Correction: Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.

ABSTRACT: [This corrects the article DOI: 10.1371/journal.pone.0234103.].

SUBMITTER: PLOS ONE Staff

PROVIDER: S-EPMC8101907 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Similar Datasets

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.

Project description: Not available

| S-EPMC7347136 | biostudies-literature

CDK inhibitor Palbociclib targets STING to alleviate autoinflammation

Project description: Not available

| S-SCDT-EMBOR-2021-53932V1 | biostudies-other

A Tissue-Specific Tankyrase Inhibitor Drives Key Developmental and Oncogenic Pathways

Project description:Tissue-specific regulation of WNT and YAP/TAZ signaling is critical for optimal organismal growth, development, and maintenance. Uncontrolled activity often leads to developmental abnormalities and aggressive cancers. Tankyrase (TNKS) is a poly-ADP-ribose polymerase (PARP) that controls both WNT and YAP/TAZ signaling. However, it is unclear how TNKS activity is regulated in a tissue and cell-type specific manner. Here, we identified the previously uncharacterized prostate-associated gene 4 (PAGE4) as a tissue-specific TNKS inhibitor. Structural and biochemical studies revealed that mechanistically PAGE4 inhibits TNKS through hijacking TNKS substrate binding pockets leading to the stabilization of TNKS substrates. In vitro cell culture and in vivo zebrafish and transgenic mouse model studies showed that PAGE4 is a potent inhibitor of TNKS and WNT signaling. Interestingly, PAGE4 is physiologically restricted to expression in select tissues and cell types, including WNT producing prostatic fibroblasts where spatiotemporal regulation of WNT signaling is critical for proper organ development. Surprisingly, PAGE4 is aberrantly expressed in hepatocellular carcinomas that bypass TNKS through mutant CTNNB1 driven WNT signaling. In vitro and in vivo tumorigenic studies revealed that PAGE4 initially function as a tumor suppressor through inhibition of WNT signaling, but upon CTNNB1 mutation becomes an oncogenic driver through YAP/TAZ signaling. Thus, we establish PAGE4 as a robust tissue-specific TNKS inhibitor that physiologically coordinates developmental WNT signaling, but genetic aberration during cancer progression re-wire PAGE4 into pro-oncogenic YAP/TAZ pathway.

2020-12-01 | GSE141323 | GEO

Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM.

Project description: Not available

| S-EPMC8151379 | biostudies-literature

Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling.

Project description: Not available

| S-EPMC3526353 | biostudies-literature

LKB1 pro-oncogenic activity triggers cell survival in circulating tumor cells.

Project description: Not available

| S-EPMC5663996 | biostudies-literature

Notch targets the Cdk inhibitor Xic1 to regulate differentiation but not the cell cycle in neurons.

Project description: Not available